These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24899660)

  • 1. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
    Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
    Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
    Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
    Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
    Mendes D; Alves C; Batel-Marques F
    J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
    Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
    Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
    Costa MF; Said NR; Zimmermann B
    Semin Arthritis Rheum; 2008 Jun; 37(6):381-7. PubMed ID: 17977585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
    Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
    J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha-induced systemic lupus syndrome.
    Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
    Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
    Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
    Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.
    Théophile H; Schaeverbeke T; Miremont-Salamé G; Abouelfath A; Kahn V; Haramburu F; Bégaud B
    Drug Saf; 2011 Jul; 34(7):577-85. PubMed ID: 21663333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.
    Lanternier F; Tubach F; Ravaud P; Salmon D; Dellamonica P; Bretagne S; Couret M; Bouvard B; Debandt M; Gueit I; Gendre JP; Leone J; Nicolas N; Che D; Mariette X; Lortholary O;
    Chest; 2013 Sep; 144(3):990-998. PubMed ID: 23744173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
    Benucci M; Nenci G; Cappelletti C; Manfredi M
    Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced systemic lupus erythematosus associated with etanercept therapy.
    Shakoor N; Michalska M; Harris CA; Block JA
    Lancet; 2002 Feb; 359(9306):579-80. PubMed ID: 11867114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
    Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
    J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.